1 - Department of Dermatology and Allergy, Comprehensive Allergy Center, Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
2 - University Hospital Montpellier, France
3 - MACVIA-France, Montpellier, France
4 - Faculty of Medicine, Transylvania University, Brasov, Romania
5 - Department of Geriatrics, Montpellier University Hospital, Montpellier, France
6 - Department of Clinical Immunology, Wrocław Medical University, Wroclaw, Poland
7 - ALL-MED Medical Research Institute, Wrocław, Poland
8 - University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy
9 - Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, Lisbon, Portugal
10 - Faculdade de Ciências Médicas (FCM), CEDOC, Universidade Nova de Lisboa, Lisbon, Portugal
- Publicação em versão integral em revista internacional. Allergy Eur J Allergy Clin Immunol. 2021 Oct 1;76(10):2952–64.
Resumo: Older adults, especially men and/or those with diabetes, hypertension, and/or obe-sity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritized to receive COVID-19 vaccines due to high risk of death. In very rare instances, the COVID-19 vaccines can induce anaphy-laxis, and the management of anaphylaxis in older people should be considered care-fully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society) Working Group has proposed some recommendations for older adults re-ceiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to man-age anaphylaxis in the older patients.
Palavras-Chave: adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people)